Form 4: Edgewise Therapeutics CEO Kevin Koch Executes Option and Sells Shares Under 10b5-1 Plan

Edgewise Therapeutics CEO Kevin Koch exercised stock options and sold 100 shares of common stock at $30 per share, while also reporting beneficial ownership through family trusts and an LLC.

Summary

• On March 7, 2025, Kevin Koch, the President and CEO of Edgewise Therapeutics, exercised stock options to acquire 100 shares of common stock at a price of $0.18 per share.
• Simultaneously, Koch sold 100 shares of common stock at $30 per share.
• Following these transactions, Koch directly owns 14,478 shares of Edgewise Therapeutics.
• Koch also has indirect ownership of 259,554 shares through KTK Family Enterprise, LLC, and 26,410 shares each through the Nicole M. Soldow Heritage Trust, Adrienne R. Koch Heritage Trust, and Matthew K. Koch Heritage Trust.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a standard disclosure of insider trading activity under a pre-existing plan. It doesn't inherently indicate positive or negative news about the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information.

Comparison to Industry Standards

• Executive compensation packages often include stock options, aligning management's interests with shareholders.
• Rule 10b5-1 plans are a standard practice among public company executives to manage their stock transactions.
• The reported transactions are typical for executives holding significant equity in their companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.
• The use of a 10b5-1 plan provides transparency and reduces concerns about insider trading.

Key Dates